Pharmacological Devices: Optimising device performance

Pharmacological Devices: Optimising device performance

The inert device market will soon become a thing of the past as medical device and diagnostic companies compete for a solution that will not only provide functionality, but also speed up and aid the healing process.

Optimising Device Performance is a report that provides the latest developments in this area and will assist companies in developing their competitive strategies. It highlights the product sectors that benefit from a combination of devices with pharmaceuticals and bioactive agents. It has specific focus on developments in bioactive device technology and highlights future potential.

The report assesses:

The global market for active devices. Major applications reviewed are cardiovascular and vascular, orthopaedics, spine repair and wound care
Technical and regulatory challenges for the drug-device combinations
The technology on the market and technology in the pipeline, examining how successful each technology is proving
The companies at the forefront of this field together with their market strategies, products on the market and in development, financial status and market shares

PUBLISHED: MARCH 2001
PAGES: 120+
REF: CBS872E
PRICE: £695/$1,460/¥167,000

For further information about this report, please contact our Customer Helpdesk on:
Tel: +44 (0)20 8332 8965 / 66
Fax: +44 (0)20 8332 8992
E-mail: [email protected]

CONTENTS
LIST OF TABLES
LIST OF FIGURES
EXECUTIVE SUMMARY
ABBREVIATIONS

CHAPTER 1 INDUSTRY OVERVIEW
1.1 Bioactive coatings and implantable devices
1.1.1 Defining the implanted device
1.2 Technological advances
1.2.1 Minimal access surgery
1.3 Biocompatible coatings
1.3.1 Coatings for devices
1.4 Biocompatible implanted devices
1.4.1 Coated stents
1.4.2 Coated catheters
1.4.3 Orthopaedic implants
1.4.4 Wound healing
1.5 Device coatings
1.5.1 Growth factors
1.5.2 Gene therapy
1.5.3 Drug therapies
1.6 Alternative delivery vehicles
1.6.1 Matrices
1.6.2 Scaffolds
1.6.3 Hydrogels or gels
1.6.4 Cell seeding
1.7 Market strategies
1.8 Competitive outlook

CHAPTER 2 BIOMIMETICS
2.1 Introduction
2.2 Technical challenges
2.2.1 Designing the successful implant
2.2.2 Large scale production issues
2.3 Biodegradable and non-biodegradable bioactive devices
2.3.1 Surface modification of permanent implants
2.3.1.1 Biocompatible polymer coatings
2.3.1.2 Amino peptoids
2.3.2 Coated metals
2.3.3 Surface induced mineralisation
2.3.4 Incorporation of bioactive molecules
2.3.5 Bioactive polymer structures
2.4 Bioresorbable devices
2.4.1 Scaffolds
2.4.1.1 Bioactive scaffolds
2.5 Haemocompatibility
2.5.1 Blood-compatible surfaces
2.5.2 Haemocompatible catheters, stents and haemodialysis equipment
2.5.3 Haemocompatibility in permanent implants
2.5.4 Haemocompatibility and endothelial cell growth
2.6 Alternative coating materials
2.7 Control of drug release
2.7.1 Dosage
2.7.2 Leaching
2.7.3 Long-term bioactivity
2.7.4 Time-sensitive drug release
2.8 Regulatory issues
2.8.1 Drug/device regulation and active implants as medicinal products
2.8.2 EU/US mutual recognition agreement
2.8.3 EU Medical Devices Directive
2.9 Competitive environment

CHAPTER 3 THE GLOBAL MARKET FOR PHARMACOLOGICAL DEVICES
3.1 The world market for medical devices
3.1.1 Market growth and trends
3.2 The global market for pharmacological devices
3.2.1 The cardiovascular and vascular markets
3.2.1.1 Trends in cardiovascular and vascular treatment
3.2.1.2 Coronary artery bypass graft procedures
3.2.1.3 Inert and bioactive stents
3.2.1.4 Vascular grafts
3.2.1.5 Heart valves
3.2.2 Catheters
3.2.3 The market for orthopaedic products
3.2.3.1 Drivers and limiters of the orthopaedics market
3.2.3.2 Cartilage repair
3.2.3.3 Bone repair
3.2.3.4 Ligament repair
3.2.3.5 Meniscal injuries and repair
3.2.3.6 Joint repair
3.2.3.7 Discectomy and degenerative disc disease
3.2.3.8 Jaw and shoulder regenerative procedures
3.2.4 Spinal cord injuries
3.2.4.1 Nerve repair and regeneration
3.2.5 Wound management
3.2.5.1 Burns
3.2.5.2 Ulcers
3.2.5.3 Wound filling
3.2.6 Periodontal applications, catheters and plastic surgery
3.2.6.1 Opportunities in periodontal repair
3.2.7 Urology

CHAPTER 4 PHARMACOLOGICAL DEVICE TECHNOLOGY ON THE MARKET
4.1 Medical device coatings
4.1.1 Antimicrobial coatings
4.1.1.1 Antimicrobial silver
4.1.1.2 Antibiotic release coatings
4.1.1.3 Antimicrobial-coated catheters
4.1.2 Antithrombogenic
4.1.2.1 Heparin coatings
4.1.3 Cell resembling coatings
4.2 The cardiovascular market
4.2.1 Stents
4.2.1.1 J&J Cordis Bx Velocity stent with Hepacoat
4.2.1.2 Biocompatibles BiodivYsio coronary stent
4.2.2 Brachytherapy systems
4.2.2.1 Cordis's Checkmate Intravascular Brachytherapy System
4.2.2.2 Novoste Beta-Cath System
4.2.3 Artificial vascular grafts
4.2.3.1 CardioTech VascuLink vascular access graft
4.2.4 Valves
4.2.4.1 Edwards Lifesciences
4.2.4.2 St Jude's Masters series
4.2.5 Vascular access catheters
4.2.5.1 ARROWgtard infection protection
4.2.5.2 Cook Spectrum antimicrobial impregnated central venous catheter
4.2.5.3 Edwards Vantex central venous catheter
4.2.6 Cardiovascular company data
4.3 Orthopaedics technology
4.3.1 Bone repair
4.3.1.1 Synthetic bone replacement technologies
4.3.2 Joint repair
4.3.3 Spine repair
4.3.4 Periodontal bone
4.3.5 Orthopaedic market analysis/company data
4.4 Wound care
4.4.1 Wound dressings
4.4.1.1 Acrymed and Westaim Biomedical
4.4.1.2 Tissue-engineered wound technology
4.4.2 Wound management company data
4.5 Urology
4.5.1 Foley catheters
4.5.2 Urethral and pelvic floor repair

CHAPTER 5 TECHNOLOGIES IN DEVELOPMENT
5.1 Device coatings
5.1.1 Antimicrobial coatings
5.1.1.1 Polyurethane ciprofloxacin coating
5.1.1.2 Carmeda BioActive Surface technology
5.1.1.3 TRC 5.1 Heparin Coating
5.1.1.4 Antirestenotic
5.1.1.5 Radioactive
5.1.1.6 Anti-inflammatory
5.1.1.7 Superoxide dismutase mimic
5.1.1.8 BioLast non-thrombogenic coating
5.1.1.9 Cell coatings
5.1.1.10 Biomimetic coatings and polymers
5.2 Scaffolds
5.2.1 Polyactive scaffold systems
5.2.2 IMMIX bioactive implants
5.2.3 Decellularised matrices
5.2.4 Small intestinal submucosa biomaterial
5.2.5 CryoLife Synergy matrix technology
5.3 Gene therapy
5.3.1 DNA devices
5.3.2 Plasmid-linked FGF-2
5.3.3 Genetically altered cells
5.4 Progenitor cell populations
5.5 Cardiovascular applications
5.5.1 Long-term heparin activity
5.5.2 Active stents
5.5.2.1 Drug-eluting stents
5.5.2.2 Radioactive stents
5.5.2.3 Gene delivery
5.5.2.4 Bio-engineered stents
5.5.3 Reprogenesis Vascugel antirestenotic
5.5.4 Heart valves
5.5.5 Vascular grafts
5.5.5.1 PolyBioMed bonding
5.5.5.2 Genetically altered grafts
5.5.5.3 Tissue-engineered grafts
5.5.6 Scar reduction
5.5.7 Catheters
5.5.7.1 CardioTech infection-resistant material
5.5.7.2 Antimicrobial central venous catheters
5.5.7.3 Balloon catheters
5.5.8 Cerebral aneurysm coils
5.6 Tissue regeneration
5.6.1 Orthopaedics
5.6.1.1 Cartilage regeneration
5.6.2 Scaffolds
5.6.2.1 Cell-seeded scaffolds
5.6.2.2 Acellular matrices
5.6.2.3 Active matrices
5.6.2.4 Growth factor impregnated matrices
5.6.3 Magnetically-tagged cells

CHAPTER 6 COMPANY PROFILES
6.1 Advanced Tissue Sciences
6.1.1 Financial overview
6.1.2 Advanced Tissue Sciences' technology
6.1.2.1 Dermagraft and TransCyte
6.1.2.2 Orthopaedic product developments
6.1.2.3 Cardiovascular research
6.1.2.4 Gene therapy
6.1.2.5 Tissue engineering, stem cells and bioactive devices
6.2 Biocompatibles International plc
6.2.1 Financial overview
6.2.2 Biocompatibles' technology
6.2.2.1 Stents, guidewires and other devices
6.2.2.2 Adsorption and bacterial adhesion
6.2.2.3 Non-thrombogenic coatings
6.2.2.4 Contact lens applications
6.2.2.5 Cardiopulmonary bypass surgery
6.2.2.6 Site- and lesion-specific coated stents
6.2.2.7 The Hunter PC-coated guidewire
6.3 Boston Scientific
6.3.1 Financial overview
6.3.2 Boston Scientific's technology
6.3.2.1 Stents and catheters
6.3.2.2 Paclitaxel
6.4 CardioTech Corp
6.4.1 CardioTech's technology
6.4.1.1 Vascular grafts
6.4.1.2 Polymer-covered vascular stents
6.4.1.3 Hydromed CTM hydrophilic coating
6.4.1.4 Endothelial cell seeding
6.4.1.5 Novel infection-resistant polyurethane coating
6.4.1.6 Scar-reducing radioactive sleeve
6.5 Cook Group Inc
6.5.1 Cook technology
6.5.1.1 Antimicrobial-coated catheter
6.6 Edwards Lifesciences
6.6.1 Financial overview
6.6.2 Edwards Lifesciences' products
6.6.2.1 Tissue heart valves
6.6.2.2 Vascular products
6.2.2.3 Heparin-coated products
6.7 ETEX
6.7.1 ETEX's technology
6.7.1.1 Bioactive substances
6.7.1.2 Surface coating and etching of orthopaedic implants
6.8 Implant Sciences
6.8.1 Financial overview
6.8.2 Implant Sciences' technology
6.8.2.1 Radioactive stents
6.8.2.2 Polymer-coated stents
6.8.2.3 Catheter-based radiation device
6.8.2.4 Ceramic coatings
6.9 Integra LifeSciences
6.9.1 Financial overview
6.9.2 Integra's technology
6.9.2.1 Dural grafts
6.9.2.2 Tissue engineering in development
6.10 IsoTis
6.10.1 Financial overview
6.10.2 IsoTis's technology
6.10.2.1 Polyactive
6.10.2.2 Rainbow coating technology
6.10.2.3 Biskin
6.10.2.4 Hybrid technology bone replacement programme
6.10.2.5 Further market opportunities
6.10.2.6 Spinal fusion and burn wound treatment programmes
6.11 Johnson & Johnson (Cordis/Biosense)
6.11.1 Financial overview
6.11.1.1 Strategic alliances
6.11.2 Johnson & Johnson's technology
6.11.2.1 RGD peptide technology
6.11.2.2 Circulatory disease management
6.11.2.3 Stent delivery of rapamycin
6.11.2.4 Artificial skin
6.12 LifeCell Corporation
6.12.1 Financial overview
6.12.2 LifeCell's technology
6.12.2.1 AlloDerm
6.12.3 Products in development
6.13 Medtronic Sofamor Danek
6.13.1 Financial overview
6.13.2 Medtronic Sofamor Danek's technology
6.13.2.1 Hepamed-coated active devices
6.13.2.2 Bioactive neurosurgical devices
6.14 OsteoBiologics Inc
6.14.1 OsteoBiologics' technology
6.14.1.1 Bone repair
6.15 Selective Genetics
6.15.1 Selective Genetics' technology
6.15.1.1 FGF-2
6.15.1.2 Gene-activated matrix
6.15.1.3 Bioactive interbody fusion cages
6.16 Smith & Nephew
6.16.1 Financial overview
6.16.2 Smith & Nephew's technology
6.16.2.1 Wound and burns management
6.17 Spinal Concepts
6.17.1 Spinal Concepts' technology
6.18 Stryker Corporation
6.18.1 Financial overview
6.18.2 Stryker's technology
6.18.2.1 OP-1
6.18.2.2 BoneSource Bone Matrix
6.19 Sulzer Medica
6.19.1 Financial overview
6.19.2 Sulzer's technology
6.19.2.1 Spinal repair
6.19.2.2 Biological meniscus implant
6.19.2.3 Ne-Osteo growth factor